DENTSPLY SIRONA (XRAY) Q3 2025 Earnings Transcript

Image source: The Motley Fool.

Date

Thursday, November 6, 2025 at 8:30 a.m. ET

Call participants

• President and Chief Executive Officer — Daniel T. Scavilla
• Interim Head, Investor Relations — Wade Moody

Need a quote from a Motley Fool analyst? Email pr@fool.com

Risks

• Global sales declined 5% as reported and negative 8% on a constant currency basis, with US sales down 22.2%, reflecting sustained weakness in key segments.
• A $263 million non-cash after-tax impairment charge was recorded due to tariff impacts and lower projected volumes in equipment, implants, and prosthetics, particularly in the US.
• Non-GAAP earnings per share declined by $0.13, with approximately half of the decline attributed to gross profit impacts from tariffs and sales mix, and the remainder from a higher non-GAAP tax rate of 32% versus 16% previously.
• Management revised 2025 guidance downward, with constant currency sales expected to decline in the range of negative 5% to negative 4% year-over-year, and adjusted EPS expected to be approximately $1.60.

Takeaways

• Revenue -- $940 million in global sales in Q3 2025, representing a 5% decrease as reported and negative 8% on a constant currency basis.
• US sales -- $291 million in Q3 2025, a decline of 22.2%, driven by lower performance across Essential Dental Solutions, AdCam, Imaging, and Implants, partially offset by growth in Treatment Centers and 22.3% growth in WellSpec.
• European sales -- $382 million, an increase of 9.9% as reported, or 2.6% on a constant currency basis, with notable growth in connected technology and labs and strong constant currency gains in the UK, France, Italy, and Spain.
• Adjusted EBITDA margin -- 18.4%, up 50 basis points versus prior year, reflecting favorable mix and tariff impacts on gross profit, partially offset by reduced spending in OpEx.
• Non-GAAP EPS -- Prior year non-GAAP earnings per share was $0.37, down $0.13; higher tax rate (32% vs. 16%) contributed about half the decline, with tariffs and sales mix comprising the other half.
• Cash flow -- $79 million in operating cash from the quarter and total cash balance of $363 million at period end.
• Shareholder returns -- $32 million returned through dividends in the quarter, with $96 million returned year-to-date.
• Goodwill & intangible impairment -- $263 million non-cash charge tied to lower expected volumes and adverse tariff impacts.
• Technologies & Equipment Segment (CTS) -- Sales decreased 7% on a constant currency basis, with European and Rest of World imaging showing growth offset by double-digit CADCAM declines in the US.
• Consumables Segment (EDS) -- Sales declined 6.2% on a constant currency basis; entire decline attributed to prior dealer prebuy impact.
• Ortho/Implants/SureSmile Segment (OIS) -- Sales down 17.1% in constant currency, or 5.8% excluding "bite" category impact; SureSmile declined low single digits, with US weakness partially offset by international gains, and IPS implant volumes fell in the US and China, with slight growth in Europe.
• WellSpec Healthcare -- Sales grew 9.3% on a constant currency basis, with growth across all regions.
• 2025 outlook -- Management revised guidance to $3.6-$3.7 billion in non-GAAP net sales and expects adjusted EPS of approximately $1.60; constant currency sales set to decline 4%-5% year-over-year.
• Strategic priorities -- Management outlined a 24-month "return to growth" plan based on four pillars: customer centricity, revitalizing US operations, empowering talent, and operational optimization to support innovation.
• CFO transition -- Departure of Chief Financial Officer Matthew E. Garth announced; "This action is not the result of any dispute, disagreement, or financial reporting matter."

Summary

DENTSPLY SIRONA (NASDAQ:XRAY) reported declining sales across core segments, with acute weakness in the US and ongoing headwinds from tariffs and lower equipment demand, leading to a material impairment charge and a downward revision of full-year guidance. Management highlighted regionally mixed performance, with Europe showing relative resilience driven by technology solutions and select country gains, while the Rest of World segment displayed flat revenues with strength in Australia and India but offsetting softness in Japan. In response to these challenges, the CEO emphasized a comprehensive action plan targeting organizational structure, customer engagement, and supply chain efficiency, while confirming expanded R&D investment and the retention of the WellSpec business for long-term value creation.

• President and Chief Executive Officer Daniel T. Scavilla underscored the need for "bold change" and urgency in execution, stating, "It's time for bold change. And we're entering a new era for DENTSPLY SIRONA."
• Investment priorities were clarified, with accelerated R&D expenditure scheduled for the fourth quarter and the establishment of new leadership in key areas, including the appointments of a chief transformation officer and a digital integration leader.
• Management addressed persistent US underperformance, attributing it to "structural approach and our execution" issues as well as the need for improved dealer and DSO strategies.
• The CEO confirmed the deployment of a multi-channel commercial approach, direct specialty sales, expanded dealer relationships, and a significant push in North American sales and clinical education initiatives.
• Capital allocation philosophy centers on business growth and deleveraging, with dividend and debt retirement under ongoing board review but no immediate shifts detailed.

Industry glossary

• CAD/CAM: Computer-aided design and manufacturing technology used for dental restorations and appliances.
• ERP: Enterprise Resource Planning system integrating business processes such as finance and supply chain.
• DSO: Dental Service Organization, a network that provides management and support services to dental practices.
• VBP Program: Value-Based Procurement initiative in China affecting medical device volume and pricing.
• WellSpec: DENTSPLY SIRONA's healthcare segment involved in urology and other medical consumables, referenced here as a growth driver beyond core dental markets.
• CTS: Technologies & Equipment Segment, consisting of dental equipment, imaging, and related technologies.
• EDS: Consumables Segment, comprising endodontic, restorative, and preventive dental products.
• OIS: Ortho/Implants/SureSmile Segment, which includes orthodontics, dental implants, and clear aligner solutions.
• AdCam: Advanced CAD/CAM products category within dental digital solutions.
• SureSmile: DENTSPLY SIRONA's dentist-directed clear aligner solution for orthodontic treatments.
• IPS: Implant Product Systems, referring to the company's portfolio of dental implant solutions.

Full Conference Call Transcript

Operator: Good day, and thank you for standing by. Welcome to the Q3 2025 DENTSPLY SIRONA Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a Q&A session. To ask a question during the session, you will need to press star 11 on your telephone. You'll then hear an automated message advising that your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Wade Moody, Investor Relations. Please go ahead.

Wade Moody: Thank you, operator, and good morning, everyone. Welcome to the DENTSPLY SIRONA third quarter 2025 earnings call. Joining me for today's call is Daniel T. Scavilla, President and Chief Executive Officer. I'd like to remind you that an earnings press release and slide presentation related to the call are available in the investors section of our website at www.dentsplysirona.com. Before we begin, please take a moment to read the forward-looking statements in our earnings press release. During today's call, we may make certain forward-looking statements that reflect our current views about future performance and financial results. We base these statements and certain assumptions and expectations on future events, that are subject to risks and uncertainties.

Our most recently filed Form 10-K and any updated information in subsequent Form 10-Q or other SEC filings list some of the most important risk factors that could cause actual results to differ from our predictions. On today's call, our remarks will be based on non-GAAP financial results. We believe that non-GAAP financial measures offer investors valuable additional insights into our business's financial performance, enable the comparison of financial results between periods, where certain items may vary independently of business performance, and enhance transparency regarding key metrics utilized by management and operating our business. Please refer to our press release for the reconciliation between GAAP and non-GAAP results. Comparisons provided are to the prior year quarter unless otherwise noted.

A webcast replay of today's call will be available on the Investors section of the company's website following the call. And with that, I will now turn the call over to Dan.

Daniel T. Scavilla: Thanks, Wade, and good morning, everyone. Let's start with slide three. I recently completed my first ninety days as CEO of DENTSPLY SIRONA. During my first week at the company, we held the Q2 2025 earnings call, where I shared my listen, learn, lead approach, along with my initial thoughts on the organization's focus areas. Since then, I've continued to assess DS through meetings with customers, partners, and employees where I've been learning our strengths and areas of improvement. These discussions have helped validate initial observations, gain alignment with my leadership team, and shape our return to growth action plans through improved performance and deliver sustained profitable growth over the next twenty-four months.

This plan requires us to go deeper, move faster, and be bolder to reshape and improve the customer experience. I believe the potential for DENTSPLY SIRONA has never been greater, and we have at our fingertips what we need to achieve this. First, I'll discuss our Q3 2025 results and full-year outlook. Then I'll share a deeper view of our return to growth action plan and its four key pillars. Before I begin, I want to note that as announced in this morning's press release, Matthew E. Garth, our Chief Financial Officer, has departed the company. This action is not the result of any dispute, disagreement, or financial reporting matter.

Matt was not the right fit for me, where I plan to take the enterprise in the finance organization. He is talented, and we wish him the very best. A transition plan is in place to ensure continuity, and that we maintain financial discipline as we select the right leader to join us driving DENTSPLY SIRONA forward.

Moving to slide four, let's discuss our quarterly financial results. For Q3 2025, global sales were $940 million, decreasing 5% as reported or negative 8% on a constant currency basis. Excluding the bite impact, sales declined 5%, and as disclosed in last year's Q3 earnings call, Q3 2024 included a $24 million one-time dealer prebuy in advance of the US ERP implementation. Adjusting for this one-time headwind, Q3 2025 sales on a constant currency basis were down 2.5%. Adjusted EBITDA was 18.4%, up 50 basis points versus prior year, driven by lower sales on favorable product and geography mix and tariff impacts that negatively impacted gross profit. This was offset by reduced spending in OpEx.

Prior year non-GAAP earnings per share was $0.37, down $0.13 versus approximately half the EPS decline reflects the impacts of sales mix and tariffs on gross profit with the remaining half driven by higher non-GAAP tax rates in the quarter of 32% versus 16% last year. This is due to shifts in profit between the US and international markets. Q3 cash from operations was $79 million and ending cash balance was $363 million. We recorded a $263 million non-cash after-tax charge related to the impairment of goodwill and intangible assets. These impairments were driven by the impacts of tariffs and lower projected volumes of equipment, implants, and prosthetic products, particularly in the US.

In the third quarter, DENTSPLY SIRONA returned $32 million to shareholders through dividends, with $96 million returned to shareholders through dividends year to date.

Now moving to Slide five. For Q3 results from a regional perspective, US sales were $291 million, down 22.2% versus prior year, driven by lower sales throughout Essential Dental Solutions, AdCam, imaging and implants, partially offset by strong performance in treatment centers, and in healthcare, our WellSpec business which delivered 22.3% growth. Adjusting for the bite impact and the one-time $24 million prior year US sales were down 9.7%. European sales were $382 million, increasing 9.9% as reported or 2.6% on a constant currency basis. Driven by growth in connected technology solutions and labs, partially offset by softness in restorative. The UK, France, Italy, and Spain had strong constant currency growth, partially offset by lower sales in Switzerland.

Germany sales were flat in Q3 versus prior year. WellSpec sales grew 5.3% in Europe on a constant currency basis. Rest of World sales were $231 million, down slightly versus prior year, with strength in Essential Dental Solutions offset by declines in connected technology Solutions and Implants. Strength in Australia and India, were offset by softness in Japan, WellSpec grew 87.3% off a small base in Q3.

Now turning to Slide six for our business segment results. CTS sales on a constant currency basis decreased 7% versus prior year, Equipment and instruments increased by low single digits, reflecting growth of Imaging In Europe and rest of world. And growth of treatment centers across all three regions, partially offset by a decline in imaging in the US. E and I growth was offset by double-digit decline from CADCAM in the US and of the world. Distributor inventory levels for both CADCAM and imaging products remain below our historical averages. Moving to EDS, which includes endo, resto, and preventative products, sales on a constant currency basis decreased 6.2% with the decline entirely attributed to the previously described dealer prebuy.

Shifting to OIS, sales in constant currency declined 17.1% excluding the bite impact OIS sales were down 5.8%. In ortho, SureSmile declined low single digits in the quarter as we saw softness in the US market partially offset by growth in Europe and rest of world. IPS declined mid-single digits in the quarter, driven by lower implant volumes in the US and China. We saw a slowdown in the activity in the Chinese market in anticipation of the implementation of the second phase of the VBP program. In Europe, IPS increased slightly. Wrapping up our segment results, sales in constant currency for WellSpec Healthcare increased 9.3% as we saw growth across all three regions.

Now I'd like to discuss the outlook for the remainder of 2025 on Slide seven. The company is revising its 2025 outlook based on the results of the third quarter tariff impacts and targeted investments we've already begun making in key areas. To accelerate growth momentum in 2026. The revised outlook includes net sales in the range of $3.6 billion to $3.7 billion and constant currency sales are expected to be in the range of negative 5% to negative 4% year over year. Adjusted EPS is expected to be approximately $1.6.

Now on Slide eight, I'd like to look forward and discuss our detailed return to growth action plans designed to improve performance and deliver sustained profitable growth over the next twenty-four months. This will be achieved by going deeper, moving faster, and being bolder and based on four pillars. Putting customers at our center, reigniting the US business to win, empowering people to power performance, and evolving operations to fuel innovation. I will now discuss the actions we will take in each pillar.

Putting customers at the center. What I've learned in my first ninety days is in our businesses where the customer is the center of everything we do, we win. I know that may seem obvious, but one of the reasons we're not growing as an enterprise is that we have some parts of the company where we can serve the customer far more effectively. By putting the customer at the center of everything we do, every employee, and every team at DENTSPLY SIRONA now starts with the mindset of delivering a better, more positive, easy to do business with customer experience to earn their share of loyalty.

The customer is defined as any practitioner who uses our products regardless if they purchase directly, through a DSO or a dealer. They're our customers. And we will partner with DSOs and dealers to deliver the timely, consistent support they need. We will achieve this by creating a global customer service and technical service organization that delivers high-quality support worldwide while maintaining the agility needed to meet local market needs. We will also enhance our support for customers and our field-based employees through simplifying interactions, speed of response, and increased strategic investments. The field is and will become even more so a strength of our company the tip of our spear.

Reigniting the US business to win, Second, we're making the return to health of our US business a top priority with a comprehensive plan to reignite growth and strengthen our commercial foundation. Under the leadership of Alvaro Dante, our new Chief Commercial Officer, we're aligning our teams, accelerating decision-making, and positioning DENTSPLY SIRONA to compete and win with greater speed and focus. Here are specific actions we're taking to drive this plan forward. Many of which are already underway. Including organizing our commercial teams to better reflect the requirements of the market with the aim of enabling improved coordination clearer strategic focus, and stronger competitiveness supported by defined decision-making processes, performance indicators, and accountability frameworks.

As mentioned before, combining customer service and technical service into a single globally led team under experienced leadership to improve the customer experience and strengthen coordination with our dealer partners. Pursuing a multichannel approach to retain direct sales in specialty areas while reengaging and expanding our network of US dealer partners in CTS to accelerate market penetration. We're also aligning with DSOs by offering simpler and more comprehensive support such as all-in-one de novo offerings, which leverages the breadth of our portfolio. Investing in our sales team to fill open rep positions expand coverage, and deploy growth-based compensation and retention tools to better serve existing customers and acquire new ones.

Increasing our investment in clinical education for dental professionals focusing on advanced training areas like connected dentistry and single visit care. At the same time, we're strengthening our sales training to better reflect the needs of dental offices giving our teams a deeper understanding of practice workflows and the tools to deliver tailored solutions that improve both clinical and operational outcomes. The initiatives outlined are focused on North America, but have clear applicability across EMEA and Asia Pac. We plan to increase regional investments in 2026 to accelerate growth. At the same time, we're exploring new go-to-market models in Asia Pac to strengthen CTS market penetration in Japan and refining our strategy in China.

As the US business gains momentum, we will strategically shift additional investments towards EMEA and Asia Pac.

Empowering people to power performance, The lead DENTSPLY SIRONA through this turnaround we're strengthening our organizational foundation to empower our people to power performance. Our teams need the right tools, systems, and information to operate effectively, supported by a greater automation and clearer priorities, with aligned leadership and bringing new expertise where needed to accelerate our progress. This balanced approach leverages the strength of our existing organization, and complements them with leaders who have deep experience in global transformations sustained growth, and consistent financial performance. With our finance organization, we're taking steps to elevate capabilities while ensuring continuity as we identify the right long-term financial leader for DENTSPLY SIRONA. As I shared at the top of the call, Matthew E.

Garth has departed the organization and a transition plan that's in place to ensure continuity and maintain financial discipline. A search for his successor led by Hydrogen struggles is underway. During the center of period, board member Leslie Vero, former chief financial officer of Xerox Corporation, will provide governance and oversight of the finance organization in her capacity as Audit and Finance Committee Chair. In our commercial organization, we're sharpening our focus on the customer experience and market competitiveness. Under the leadership, of Chief Commercial Officer, Alvaro Dante, we're strengthening execution in North America and rebuilding the US commercial leadership structure.

This includes a search for a new US VP of sales and broader efforts to deepen partnerships, improve service delivery, drive customer loyalty. Coming from a distinguished career at Johnson and Johnson, and given Alvaro's experience in the orthopedic industry, knows how to fix customer experience, and to enhance our approach in competitive and evolving markets. We've also established a transformation office responsible for oversight of our return to growth plan. This office will advance our enterprise AI and automation strategy fundamentally improving how we work. To lead this critical effort, Dustin Shields has been appointed chief transformation officer joining DENTSPLY SIRONA in December. Dustin brings extensive global experience in commercial and operational functions, integrations, and business optimization.

Most recently at Globus Medical. Under his leadership, the transformation office will focus on delivering cross-functional improvements that enhance efficiency, agility and long-term value creation. We've also appointed a leader of digital transformation who will lead the integration of AI across our operations to increase speed, strengthen data-driven decision making, and improve the effectiveness of our support functions.

Evolving operations to fuel innovation. With a commercial organization more closely aligned to customer needs, and improved product development processes, we'll focus our investments on innovation that help clinicians enhance care, streamline workflows, and grow their practices. In parallel, we'll continue to increase and accelerate R&D investments to improve the health of our commercial engine. We're also taking steps to enable our supply chain to move faster and go deeper than before to create stronger, more profitable and scalable manufacturing distribution network. Building on the ongoing work of the supply chain transformation team.

This includes a plan to enhance operational efficiencies through resource consolidation, standardized packaging, and establish more advanced planning and forecasting to favorably impact working capital and product cost. We need to further streamline our support department cost structures to optimize resources, processes, and systems to reach benchmark efficiency levels. Reduce complexity, release capital to be redeployed into our commercial and innovation priorities. This will be accomplished by implementing common processes, common systems, and establishing regional support centers. This will include a significant reduction in legal entities and the continued implementation of SAP as our global ERP system. We plan on deleveraging the business through profitable growth and disciplined execution to drive improved EBITDA.

Working capital and cash flow, to support future capital needs debt reduction and shareholder returns. The WellSpec business will be a key role in achieving our financial goals. As previously announced, following an evaluation of strategic alternatives for WellSpec, we determined that retaining the business will deliver greater financial and strategic benefit to shareholders than the other options available. Specifically keeping the business as part of our portfolio allows us to realize previous investments not yet monetized, while benefiting from a strong cash flow generation and preserving optionality for future growth beyond dental. As evidenced by our recent results, we know how to penetrate this market and grow this business.

Moving to Slide nine, In summary, we made progress over the past two years in footprint consolidation SKU rationalization and resource streamlining. We need to move faster and act bolder to reshape the customer experience of strengthen our competitiveness in the dental market. I'm continuing to work through my onboarding to better understand the complete enterprise and market to set the appropriate financial targets. But we expect to be able to free up additional capital in our operational structure and products while reaching benchmark levels in our support functions improve rep effectiveness.

Accomplishing this will free up capital to invest in additional field-based resources, increase rep and clinical education, and higher levels of investment and innovation to drive growth and shareholder return. I'll end my formal remarks with a statement I open with. I believe the potential for DENTSPLY SIRONA has never been greater. I recognize that the company has undergone change over the last few years. The change has not been fast enough for you or the DENTSPLY board. That is why I stepped into the seat at their request. It's time for bold change. And we're entering a new era for DENTSPLY SIRONA. One that's rooted in discipline, ownership, acting with urgency, and a mandate to deliver results.

Our board of directors and my leadership team believe deeply in our ability to reposition DENTSPLY SIRONA as the market leader it once was and will be again. We're committed to doing the work necessary to get there. Even in even if it means making tough decisions. I couldn't be a for this more than anything in my life. I mean, I'm excited to do this and drive for forward with this making changes. I look forward to keeping you up to date on our progress, and I'm committed communicating with you in a direct and transparent manner every step of the way. Thank you. We will now open the call for questions.

Operator: Thank you. As a reminder to ask a question, you will need to press 11 on your telephone and wait for your name to be announced. To withdraw your question, please press 11 again. Please limit yourself to one question. Please stand by while we compile the Q&A roster. Our first question is from Elizabeth Anderson with Evercore ISI. Your line is open.

Elizabeth Anderson: Hi, guys. Good morning, and thank you for the question. I was wondering if you could maybe talk a little bit more about the US market. I think based on what you put in the slide, excluding the one-time items, it looks like it was still down about 10% year over year. So, you know, could you just sort of talk about where that is? Is that a result of the sales situation? Is it a lingering impact of the sort of prior Patterson situation? Just a little bit more color on what you see driving those shorter-term results would be very helpful. Thank you.

Daniel T. Scavilla: Thanks, Elizabeth. I think it's really a list of many things. What I'm gonna say is our focus in the US from our structure and how we go out that competitively is one thing throughout the products. I think it's the relationship with the dealers that we need to make a move on. Honestly, getting deeper with the DSOs and more meaningful strategies. Many of these things all come together. It's not just one area. I really think it's more about our structural approach and our execution in the US market. And how we, as an organization, can give our team the better tools to do that throughout the portfolio in a better way.

That's really what the return to health plan is about. Is addressing what I see as shortcomings that we can allow to continue and drive improvement in each one of these segments with a deeper focus through structure, and funding.

Operator: Thank you for your question. Our next question is from David Saxon with Needham and Company. Your line is open.

David Saxon: Great. Good morning, Dan. Thanks for taking my questions. So I just wanted to ask on this returning to profitable growth, kind of framework over the next twenty-four months, I guess, should we think about the cadence of getting to growth over that two-year period? Is that kind of should we think about flat next year? Or any guardrails around 2026 growth? And then just in terms of that target of growth, like, is that absolute growth, or is that market growth? Would love just some more color there. Thanks.

Daniel T. Scavilla: Thanks, David. Hey. I appreciate the question. You know, listen. My desire is to return to growth tomorrow. I would say don't model that just yet. What I do need is a little more time. We're going through the 2026 plan now. And I'm really working with every department in every country to do this with the team. So give me a little bit of time to come back at this. You know, I will tell you it's not a January 1 everything's rosy. But it sure can't be that you're exiting the year the same way. And so how we lay out those sequential improvements, I need a little more time to refine.

But I require that we have sequential improvements as we get through the year. I just need more time to figure out when I can tell you with confidence when they begin at section of next year.

David Saxon: Okay. Thanks for that. And then just in terms of capital allocation, I believe you talked about deleveraging in the script. So, you know, can you just remind us your philosophy around capital allocation? And specifically on the dividend, like, how important is that? Are there areas in other parts of the business or, you know, mechanics that you could direct that cash?

Daniel T. Scavilla: Yeah. You got it, David. Listen. I think that is a legitimate question. I think the discussing dividend and its value is something we need to explore further with the board with the shareholders to understand how important is that in adding shareholder value, where could that be used differently. The main tool of deleveraging isn't buying down the shares. We're actually retiring debt. To me, it's about growing the business first through the US, and then consistently through the rest of the world. To raise EBITDA so that your ratio changes. I really think it's more about growing that piece of it, the denominator, if you will, that is the health of this.

And, yes, with that comes better profit, better cash flow, which we then can and will at some point redeploy into debt retirement and when needed, share repurchase.

Operator: Thank you for your question. Our next question is from Jonathan Block with Stifel. Your line is open.

Jordan Bernstein: Great. It's Jordan Bernstein on for Jonathan Block. Thank you for taking our question. Just on the R&D aspect of the return to growth action plan. I heard some recent comments from you about trying to take that number up. And accelerating investments in R&D. Just if you could talk through that dynamic and is that a multiyear type of acceleration? And where your heads are at for the R&D organization. Thanks.

Daniel T. Scavilla: Yeah. Great question, Jordan, and thanks for it. So a couple of thoughts here. One of the reasons I'm adjusting down EBITDA now for this year is we are pulling forward millions of dollars of R&D investment into the fourth quarter that will help us position better strength in '26 and beyond. And so we are beginning that I would like to get up to the right benchmark. You know, I know we've always tossed around six to 7%. We'll evaluate that. It's probably a likely thing. I'm not sure we can get there in one fell swoop. I am looking at that now. And while I have the desire, we will increase the investment in R&D.

I'm also gonna look deeper with the R&D leadership to make sure we're spending it efficiently. And that we are spreading it out to make sure that we mitigate risk. And so there's a couple of steps there as well of are we really spending the dollars we today in the best way? And then once we have that in a good spot, how do we increase it in a way that maximizes the output for the market and for the shareholders.

Operator: Thank you. Our next question is from Jeffrey Johnson with Baird. Your line is open.

Jeffrey Johnson: Thank you. Good morning. Dan, maybe I could just follow-up and stay on the track you were just on, on the R&D side and really the OpEx side. If I look at the guidance takedown for this year, I mean, no real surprise to see a new CEO come in and kind of flush the current year out, and I think all that makes sense. But it looks like maybe your OpEx spending R&D included, going up maybe $50 million in the back half of this year to kind of get to that new guidance range.

Is that something we should think about as $50 million in the second half of this year up and we carry that over to another $100 million next year, just to annualize that? Is that kind of the new run rate spend? And if it is, I know you're nowhere close to talking about 2026 at this point. But the street's hanging out at, 16% EBIT margin. Feels like to me, you have to take OpEx spend up two to three points, maybe we should sharpen our pencils on that 16% op margin. Thank you.

Daniel T. Scavilla: Yeah, Jeff. Again, appreciate that too. And like I said, let me rustle through 2026 with the team and see. The real thing I'm doing right now is taking a loan. To increase investments so that as we go forward and we find efficiencies, we can actually make it self-funding. So I don't think it's a new add-on top thing. It's a I'm gonna pull some money up now. Get this engine running, and as we find efficiencies and redeploy it, I'm gonna expect to see decreases over time in those OpEx numbers with an increase in EBITDA.

But, again, to jump-start it, I'm gonna pull down, as you just said, some EPS invest in the right areas, so that we can start delivering these efficiencies I've talked about as we get through 2026. And into 2027.

Jeffrey Johnson: Alright. Fair enough. And I've been jumping between calls. So if you ask us to hold the one call or question, I apologize. But I'd like to hear on the European market. I don't know if you're still doing some of the surveys that your predecessor was doing. But, you know, some of our checks and I think even if we look at two Q results from some of the manufacturers and the dealers out there, it seems like the Europe dental market has maybe gotten back on a little bit better footing and really even the international market ex Canada.

So we'd love to just kinda hear your overall arching view of the international markets at this point, market more so even than your performance in the quarter? Thanks.

Daniel T. Scavilla: Yeah. You got it. So a couple of things. We do our surveys every six months. We didn't do it for the third quarter, with that. But nonetheless, we didn't see any drastic shifts from where we had done. And, anecdotally, as I was out in the field and talking with people, you know, a few people said it would slow down. A few people said it'd speed up. So I'm gonna kinda call it as kinda normal and nothing changed. The European side's interesting because while I do think it may be improving, I think the credit of the growth in Europe really goes to our leadership team. I think the person leading it is a fantastic leader.

Who's done a great job organizing the resources cross-functionally and driving growth.

Operator: Our next question is from Erin Wright with Morgan Stanley. Your line is open.

Erin Wright: Hi. Great. Thanks so much. How are you thinking about your relationship with distributors? I think you talked a little bit about kind of supply chain in your prepared remarks, but how does this, you know, intertwine with some of your strategies around return to growth and profitable growth and are you entertaining more of a hybrid approach or not? What makes sense over the longer term? And I'm sure there's still stuff that's up in the air, but curious your view right now as it stands.

Daniel T. Scavilla: Yeah. Thanks, Erin. Listen. I think, like many people in the market, we need to look at this with open eyes, and I think there's several ways to get there. In my prepared remarks, I called out a multichannel approach. And so what I am signaling is we have direct businesses, and we intend to keep those. And go more direct in those areas and support them holistically. Anything with our disposables that we use, I'm saying I think that's fine. I'm not looking to make any meaningful shifts there and keep those alone.

But reengaging with dealers Shine and Patterson, when I say that, and new dealers, which I won't call out at this point so that we have a broader reach and more presence I see that as the model that we need to use to go forward. I have personally spoken with all of the CEOs. We have these in play. I'm not gonna comment further on that because they're all at several different stages of maturity with where we can line in or not. But I would envision us next year having that locked in a way that is beneficial for everybody.

Operator: Thank you for your question. Our next question is from Vikramjeet Singh Chopra with WS. Your line is open.

Vikramjeet Singh Chopra: Hey. Good morning. A couple of questions for me. So on this return to growth action plan, Dan, I appreciate it early. But can you just talk about some of the key milestones that you'll use to measure success for each of the pillars? And then I had a follow-up, please.

Daniel T. Scavilla: Yeah, Vikramjeet, got it. So, you know, let's start with the, obviously, focus on the US market there. I'm really setting out metrics which are obviously gonna be stabilizing sales and then returning into growth over some period of time. It's gonna be one of the key metrics. Doing that by actually hiring out and retaining reps is gonna be a key one. The rate of training we do for not only the rest but our clinical partners as well will be another key metric through these investments. So as we start training more and seeing more of both the field and the dentist, that's gonna be key. Holding on to them is gonna be key.

Seeing the sales turn a resort as a result of that is gonna be one of the major moves that I see. And I didn't mention this in my prepared remarks, but having a stronger presence in universities and teaching institutions is a focal point as well. To create those long-term seeds. And now while we're there currently, again, we need to go deeper there and be more present to create that longer-term health. That's really one of the things. You know, I've already called out what's almost finished when it comes to the organizational build to supplement a great team with even stronger talent that's out there that way.

I think with the supply chain and operations, there's really a couple of there. We're going to see a lift in gross profit naturally as we get through these things. And certainly moving facilities or people and all that take a longer term. That doesn't pop within a quarter. With the R&D, we'll see it as a percent of sale on product launches. So I think they're really the main ones. Right? If we know how to free up cash, and we see changes where we can redeploy this, we watch the sales stabilize and grow. And as a result of that, we see the profit lift through our customer experience.

I think they're the ones that I'm trying to wrap around now. Make sure the team is aligned with that. In a simplified way so we know how to react faster and move and address these as needed.

Vikramjeet Singh Chopra: Great. Appreciate the color. And a quick follow-up question. You know, you recently appointed Aldo Denti as your chief commercial officer. Just curious to get your early thoughts and what impact you expect him to make over the coming months. Thanks, Dan.

Daniel T. Scavilla: Yeah. Thanks, Vikramjeet. So Aldo's honestly a great one. I had the opportunity to work with him side by side when we were in Johnson and Johnson Vision Care. And that company needed a turnaround. And we had come in with several people, and we're all part of bringing that back to the strength that it had. And he was a driving force of that in the commercial side of that coming in. You know, again, his role in orthopedics and J&J, which is no small task running that, really had a lot of activity. So bringing that strength and that experience with a known person to come side by side with me is really important to me.

I think that his drive to actually create a focused, trained, and well-resourced commercial team is going to be one of the keys here. I think that his professional approach out with dealers and DSOs will be a lift for us. I think, again, he's a main ingredient.

Operator: Thank you for your question. Our next question is from Michael Cherny with Leerink Partners. Your line is open.

Ahmad: Hi. Good morning. This is Ahmad on for Michael Cherny. Appreciate the color on the return to growth action plan and fully understand that FY '26 planning is still underway. But if we think about things bigger picture, which areas of your business do you think are best positioned to start stabilizing growth? Both from a competitive and innovative standpoint? Thank you.

Daniel T. Scavilla: Yeah. It's a good question. And, you know, my easy answer is all of them. But at the end of the day, each one of these requires a different approach. So the CTS move is more about getting the dealers lined up trained, and out with us. I think the biggest part of changing both customer service and technical service under one team and one focus be a major lift in not only the ongoing customer experience, but new customers through the implementation of capital and training. And so those things are gonna be one of the big return to health type of items.

I think setting up implant strategies and how we can get the right training and the right holistic approach and using DS Core is one of the drivers of that will be a major thing to go through. And, while strong in EDS, you know, making sure that we can continue to have the right investments in ENVEL, the right training with those type of things throughout EDS are all gonna be key to lifting them up. So, really, if you ask me, is one more important than the other? The answer is no. That's the benefit of having a diverse portfolio and it's well balanced. But they all require different approaches, and they're all addressed in this plan.

Operator: Thank you. Our next question is from Michael Sarcone with Jefferies. Your line is open.

Michael Sarcone: Good morning, and thanks for taking the questions. I guess I'll ask my two upfront. Just first, you know, can you talk about the characteristics you're looking for in a new CFO? And then just related to that, Dan, I guess, how do you think about your guidance philosophy right now? And do you expect that may change as you bring on a new CFO?

Daniel T. Scavilla: Michael, good questions. You know, looking for main attributes of CFO, and I'm not saying that the person before didn't have these, but what I really need right now is a person who can dig down into the data and get the meaning metrics that we need and then in a consistent fashion, communicate those and educate the team to follow those to go. Right now, we have plenty of data, but how we use it isn't the best way. And so I really need someone to harness all of that power to create the focus we need to show the metrics in driving this return to health thing. That's first and foremost.

An enterprise leader right now who has deep experience throughout so that they can look at this and work with all of us to guide us through and help us do it is gonna be one of the key factors that are out there. So it's kind of both. A broad person with a lot of strategy who can dig very deep and use numbers and make sure that everyone understands and follows along. Communication is gonna be key. Guidance strategy, I would say, look where I came from. I'm gonna follow that when we get this back to health. Right?

It's one of those ones where we put out conservative estimates with the goal to be raised as we go forward. Demonstrating a cadence of sustained profitable growth. That's ultimately where I wanna get to. I don't think that would change within CFO coming in. I think that's gotta be the mantra of this company going forward. We need the right person to fit that approach.

Operator: Thank you. Our next question is from Allen Charles Lutz with Bank of America. Your line is open.

Allen Charles Lutz: Good morning, and thanks for taking the Dan, you mentioned a lot of different investment areas in your prepared remarks. Global customer service and technical service organizations, clinical education, shifts in regional spending. Would think that not all of that spending is going to take place in the fourth quarter. Can you talk about what you are spending money on in the fourth quarter? And maybe what we should expect to start in 2026?

Daniel T. Scavilla: Yeah. It's a great question, and thanks for it. So listen. There's a couple things, and I'll I won't lay out every single put and take here for you. But there are big moves that we need to make to free up some of the things that we have done historically that don't make sense these days. Some of those will involve some penalties that we're gonna pay in the fourth quarter to create freedom to free up cash as early as the first quarter. So I'm taking a few hits to free up some strategic moves that allow us to go into that right away into next year.

The fourth quarter, there is an acceleration of R&D that I have set up to go. And while we don't have the execution of clinical education, establishing those programs, and putting in place anything that we can do for that is there. So I would tell you is some acceleration in R&D, a little bit of prep work in the clinical side, You mentioned customer service, tech service. That probably won't have an impact in the fourth quarter because their existing people were we are reorganizing we're beginning to recruit, but most likely will be negligible in the fourth quarter, more prominent. By the first half of the year is really where I'm going with that.

Operator: Thank you. Our next question is from Brandon Vazquez with William Blair. Your line is open.

Brandon Vazquez: Hey, Dan. Thanks for taking the question. I just want to ask kind of a high-level question on kind of the initiatives you've laid out here. Obviously, encouraging to see kind of an action plan here. But this story has been a bit of a you know, it'll be this is my phrase, maybe not yours, but the story under the prior management team has been a turnaround story. And then a little bit now, it looks like once again, again, my phrase, a bit of a turnaround story again. Many of the initiatives here feel like ones that we've been focused on for years, frankly, like getting closer to the customers and supporting them, improving efficiencies.

So I guess what would be helpful is can you just talk a little bit at a high level about what of these initiatives do you think are incremental to what has been attempted to turn things around at DENTSPLY SIRONA in the past couple of years that you think will start to eventually lead to some more durable improvements? Thanks.

Daniel T. Scavilla: Yeah. I think that is a great question. And so I'll give you a couple of thoughts. Right? There is no doubt that the customers, the employees, and the board are tired. Right? There's fatigue of coming through with these words and not quite getting where we need to go. My assessment would be while there are many right things that were done in the past, I feel like we were trimming branches when we should be cutting down trees. So, when I talk about going faster, bolder, deeper, I think that's really what I mean with that. And a lot of these things were in the right move, but not deep enough to go.

And, I think Aldo and, Dustin and I have experience in these that we can bring in, but I don't know was there as strongly as before. Now there's great folks on the team. Who are already in place, but I think the real thing is to drive deeper and push there. And it is a turnaround story. And the goal for me isn't to convince you why we know how to do this or that I'm the guy. I'm gonna prove it to you through results. Just gotta get past the talk and into the action. And I think there's enough talk that's been done.

It's time to start getting this done through execution and pointing to the numbers as opposed to saying where it will be.

Operator: Thank you for your question. Our next question is from Kevin Caliendo with UBS. Your line is open.

Dylan Finley: Thank you. This is Dylan Finley on for Kevin. Wondering if you could talk a little bit about implants. You go direct there, so, you know, not necessarily impacted by your relationships with dealers in that area of the market. What are the specific pain points that you're facing there today? And why do you think your predecessors have not been able to close the gap within the market?

Daniel T. Scavilla: Yeah. Again, good question. I can't answer why people before me did or didn't do things because I wasn't here. So I'll focus really on where we're gonna go from here. I don't think we have the right amount of reps present throughout the world. I'm not convinced they have the right training. I don't believe the branding and coordination is laid out in a way that can add strength. I don't think we're leveraging some of the other infrastructure like a DS core type program that we have to benefit these. I think all of those have to occur with a significant increase in training, not only of the reps but of the dentists. Of our products.

And quite frankly, in that area, we need to be present. It's honestly not that different than orthopedics. Where you need someone there in the room, someone well trained who can offer a lot of optionality out for the dentist. And I think we've got to take that type of model and apply it more effectively here than it has been done in the past.

Operator: Thank you for your question. This concludes the question and answer session. Thank you for your participation in today's conference. This does conclude the program. You may now disconnect.

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. Parts of this article were created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.